Laser zaps brain tumor, then chemo moves in: new combo trial opens

NCT ID NCT07145112

Recruiting now Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a two-step approach for glioblastoma that has come back after standard treatment. First, doctors use a laser guided by MRI to heat and destroy part of the tumor. Then, within a week, patients take the chemotherapy drug lomustine. The study will enroll 20 adults to see if the combination is safe and doable, and will track survival for up to 2 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lomustine (CCNU) chemotherapy
What this could lead to: If successful, this could point toward a new treatment option for recurrent glioblastoma that combines heat-based tumor destruction with chemotherapy.
What could go wrong: This is a very early Phase 1 trial with only 20 participants, so safety and feasibility are the main goals. The combination may cause serious side effects or not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

University of California Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95827, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.